BioVie Inc (NASDAQ:BIVI) has announced additional preliminary findings from the Parkinson’s disease Phase 2 trial of its drug NE3107, showing a significant improvement over the current standard of care (SOC).
The preliminary findings show that significantly more patients treated with NE3107 were considered to be in what’s called the “on” state of muscle control in the morning after withholding their usual (SOC) for at least 8 hours before taking their usual morning Parkinson’s medications when compared to a placebo.
Parkinson’s patients typically have rigid muscles and difficulty getting out of bed in the morning, which is referred to as the muscles being in an “off state.” Conversely, having sufficient muscle control is the "on" state, which is crucial for better movement and stability
Parkinson’s and vagal nerve stimulation, promising human studies.
